RESTORE: A single-arm, open-label phase II trial of bipolar androgen therapy (BAT) in men with metastatic castration resistant prostate cancer (mCRPC)—A comparison of post-abiraterone (Abi) versus post-enzalutamide (Enza) patients (Pts).

Mark C. Markowski,Hao Wang,Michael T. Schweizer,Michael A. Carducci,Channing J. Paller,Benjamin A. Teply,Mario A. Eisenberger,Jun Luo,Emmanuel S. Antonarakis,Samuel R. Denmeade

RESTORE: A single-arm, open-label phase II trial of bipolar androgen therapy (BAT) in men with metastatic castration resistant prostate cancer (mCRPC)—A comparison of post-abiraterone (Abi) versus post-enzalutamide (Enza) patients (Pts).

2020

Mark C. Markowski
Hao Wang
Michael T. Schweizer
Michael A. Carducci
Channing J. Paller
Benjamin A. Teply
Mario A. Eisenberger
Jun Luo
Emmanuel S. Antonarakis
Samuel R. Denmeade

5576Background: A paradoxical inhibition of cell growth has been observed in both androgen-sensitive and castration resistant prostate cancer cell lines following the addition of high-dose testoste...

Keywords:

Oncology
Abiraterone
Enzalutamide
Androgen Therapy
open label
castration resistant
Pathology
Internal medicine
Prostate cancer
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations